# A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

> **NCT06047548** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 441 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06047548
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-20
- **Primary completion:** 2026-01-20
- **Final completion:** 2026-01-20
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047548, "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06047548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*